Further investigation indicated that the IL-6/JAK2/STAT3 pathway was preferentially active in CD44+CD24− breast cancer stem cells, and inhibition of JAK2 decreased the number of cancer stem cell number and blocked the growth of xenografts in mice [20]. The gene discussed is JAK2; the disease is breast carcinoma.